Clinical Trial

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

Name: Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors — clinical trial record (NCT07374848)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.

Protocol Amendment History 1 change

notable Trial sites expanded: 2 -> 5 locations 2026-05-29

Trial Details

NCT Number	NCT07374848
Lead Sponsor	Zai Lab (Shanghai) Co., Ltd. Collaborators: Zai Lab (US) LLC
Conditions	Solid Tumors, Sarcomas
Enrollment	180 participants
Start Date	2026-03-02
Primary Completion	2028-08 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-23